Additionally, a substudy of the EXAMINE trial, involving 5380 patients with recent ACS and type 2 diabetes mellitus, showed that cystatin-C was significantly associated with the composite endpoint (nonfatal MI, nonfatal stroke, or CV death) and mortality in this particular category of patients [56]. The gene discussed is CST3; the disease is stroke disorder.